• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Omar Ford

Articles by Omar Ford

Results of INSITE trial published in International Journal of Spine Surgery

March 10, 2015
By Omar Ford
Newly published data from SI-Bone's (San Jose, California) INSITE (Investigation of Sacroiliac Fusion Treatment) trial support the use of the firm's implant in patients. Results from the prospective multi-center randomized trial were published in the International Journal of Spine Surgery (IJSS), a peer-reviewed, PubMed-indexed journal and official journal of International Society for the Advancement of Spine Surgery (ISASS;Aurora, Illinois) .
Read More

FDA places a hold on enrollment for ENDO Trial due to hepatic abscess

March 9, 2015
By Omar Ford
In what can only be described as a dramatic setback for the company, GI Dynamics (Lexington, Massachusetts/ Sydney, Australia) is reporting that the FDA has placed a hold on enrollment in the firm's ongoing pivotal clinical trial of EndoBarrier Therapy. The hold comes after there were four cases of a bacterial infection of the liver or hepatic abscess reported in the ENDO Trial. Upon the news, stock from the company plummeted.
Read More

MDD's Diagnostics Extra

March 6, 2015
By Omar Ford

SIR Conference 2015: Change is the only constant in the healthcare industry

March 6, 2015
By Omar Ford
ATLANTA — If there's one thing that's for certain, it's that eventually things will change. Panelists at the Society of Interventional Radiology (SIR; Fairfax, Virginia) spoke about change, particularly in healthcare and what players in the space can expect.
Read More

SIR Conference 2015: Image-guided therapy helps in treatment of severe migraines

March 5, 2015
By Omar Ford
ATLANTA — An interventional radiology treatment for migraines is garnering significant interest and attention after research from a retrospective study was presented at the Society of Interventional Radiology's (Fairfax, Virginia) Annual Scientific meeting this week.
Read More

SIR Conference 2015: 3-D printing gaining momentum as delivery method for medication

March 4, 2015
By Omar Ford
ATLANTA — 3-D printing could offer up a more viable method of delivering medication over traditional devices according to a study that was presented at the Society of Interventional Radiology's Annual Scientific Meeting this week. Researchers and engineers collaborated to print devices that were bioactive.
Read More

SIR Annual Meeting 2015: Reimbursement, regulatory hurdles are pains shared in markets across the globe

March 3, 2015
By Omar Ford
ATLANTA — Just how is interventional radiology thriving in countries whose healthcare systems measure quality and outcomes as a way to control costs? A panel at this year's Society for Interventional Radiology (SIR) meeting held in Atlanta tackled this point head on as radiologists from across the globe spoke on regulatory issues and reimbursement barriers.
Read More

First patient completes Hemopurifier treatment protocol in Aethlon study

March 2, 2015
By Omar Ford
Aethlon Medical (San Diego), a company that specializes in developing targeted therapeutic devices to address infectious diseases and cancer, said that the first patient enrolled in the company's FDA approved feasibility study has completed their full Hemopurifier treatment protocol without any device-related adverse events.
Read More

Home court advantage non existent for med-tech

Feb. 27, 2015
By Omar Ford
A couple of weeks ago I had the opportunity to interview a company that was undergoing a pivotal trial in the U.S. The company had actually received approval from the FDA to use a second generation device in the trial - because the device was already approved in Europe and had been advanced to its second iteration. While this has been an issue for a while in the med-tech space - the fact that FDA can sometimes lag behind during the approval process to this degree is a bit troubling. To my mind it hampers innovation in the U.S....
Read More

MDD's Diagnostics Extra

Feb. 27, 2015
By Omar Ford
Previous 1 2 … 64 65 66 67 68 69 70 71 72 … 227 228 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 29, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 29, 2025.
  • Boston Scientific Acurate Prime Aortic Valve System

    In TAVR setback, Boston Sci pulls plug on Acurate valves

    BioWorld MedTech
    Boston Scientific Corp. reported the latest setback in its transcatheter aortic valve replacement (TAVR) aspirations with the news that it is officially...
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe